HR Execs on the Move

Checkmate Pharmaceuticals

www.checkmatepharma.com

 
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate`s product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body`s innate immune system to attack tumors in combination with other therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Barry Labinger
President and Chief Executive Officer Profile
Arthur Krieg
Chief Executive Officer Profile
Arthur Krieg
Founder and Chief Scientific Officer Profile

Similar Companies

Synergy Health Partners

Synergy Health Partners is the car accident doctor you can trust. We offer chiropractic treatment, physical therapy, and massages.

Ferring Research Institute

Ferring Research Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Lehigh Valley Technology

Lehigh Valley Technology is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

CSL

CSL is a global biotech leader that develops and delivers life-saving medicines to treat disorders such as haemophilia and primary immune deficiencies, and vaccines to prevent influenza. They have over 30,000 employees worldwide and are committed to co...

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.